Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.043|
|52 Week High||AU$0.017|
|52 Week Low||AU$0.063|
|1 Month Change||7.50%|
|3 Month Change||-15.69%|
|1 Year Change||95.46%|
|3 Year Change||13.16%|
|5 Year Change||514.29%|
|Change since IPO||-93.23%|
Recent News & Updates
We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Patrys ( ASX:PAB...
|PAB||AU Biotechs||AU Market|
Return vs Industry: PAB exceeded the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: PAB exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: PAB is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: PAB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer, triple negative breast cancer, and glioblastoma.
Patrys Fundamentals Summary
|PAB fundamental statistics|
Is PAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAB income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0022|
|Net Profit Margin||-303.57%|
How did PAB perform over the long term?See historical performance and comparison
Is Patrys undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: PAB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAB is overvalued based on its PB Ratio (6.5x) compared to the AU Biotechs industry average (4.9x).
How is Patrys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Patrys performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAB is currently unprofitable.
Growing Profit Margin: PAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAB is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.
Accelerating Growth: Unable to compare PAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).
Return on Equity
High ROE: PAB has a negative Return on Equity (-33.74%), as it is currently unprofitable.
How is Patrys's financial position?
Financial Position Analysis
Short Term Liabilities: PAB's short term assets (A$12.4M) exceed its short term liabilities (A$849.9K).
Long Term Liabilities: PAB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PAB is debt free.
Reducing Debt: PAB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAB has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 6% each year.
What is Patrys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD, serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology....
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD446.23K) is above average for companies of similar size in the Australian market ($USD302.45K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Board: PAB's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.4%.
Patrys Limited's employee growth, exchange listings and data sources
- Name: Patrys Limited
- Ticker: PAB
- Exchange: ASX
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$78.612m
- Shares outstanding: 1.83b
- Website: https://www.patrys.com
- Patrys Limited
- 100 Albert Road
- Level 4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.